Buparlisib (BKM120, NVP-BKM120)

Catalog No.S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

Size Price Stock Quantity  
In DMSO USD 272 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 38 Publications

6 Customer Reviews

  • NLGN3 mRNA expression in SU-pcGBM2 cells after 12 hr exposure to vehicle, 50 nM NLGN3, 100 nM BKM120, or 50 nM NLGN3 + 100 nM BKM120.

    Cell, 2017, 161(4):803-16. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Western blot analysis of cleaved caspase 3 in T cell-enriched PBMCs.

    J Hematol Oncol, 2016, 9(1):113. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • AN3CA (A) and JHUEM2 (B) cells were treated for the indicated times with DMSO, 0.3 μM BGJ398 (BGJ), 0.3 μM GDC-0941 (GDC), 0.6 μM BYL719 (BYL) and 0.6 μM BKM120 (BKM) alone or in combination. Cell lysates were immunoblotted with antibodies for phospho-AKT (Ser473), total AKT, phospho-ERK (Thr202/Tyr204), ERK2, phospho-S6 (Ser240/244), total S6, phospho-4EBP1 (Thr37/46), total 4EBP1, total PARP and cleaved PARP. Tubulin was detected as the loading control. Western blot analysis of AN3CA and JHUEM2.

    Mol Cancer Ther, 2017, 16(4):637-648. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • One customer. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MoGzR5l1d3SxeHnjJGF{e2G7 Mn71O|IhcA>? MWnEUXNQ MmDTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCHNUS1T{BufXSjboSge4l1cCCJSUWwJI9nKDBwMECwNVU5KM7:TR?= MYiyOFkxODJ4Nh?=
DU145 Mm\aR5l1d3SxeHnjJGF{e2G7 NWTtbXcyPzJiaB?= MWHEUXNQ M{nMPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGW6cILld5NqdmdiTFvCNUBufXSjboSge4l1cCCJSUWwJI9nKDBwMECwOFM2KM7:TR?= NXPaRlJMOjR7MECyOlY>
A2780 NXLuOXpES3m2b4TvfIlkKEG|c3H5 M{fCeVczKGh? MYrEUXNQ NFzWU2pEgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3OzVizszN MUCyOFkxODJ4Nh?=
U87MG M2X2dGN6fG:2b4jpZ{BCe3OjeR?= MWW3NkBp MV3EUXNQ NWrJbllyS3m2b4TvfIlkcXS7IHHnZYlve3RiUGTFUk1l\W[rY3nlcpQhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDHTVUxKG:oIECuNFAxPjl6IN88US=> MnjVNlQ6ODB{Nk[=
A2780 M2eySWZ2dmO2aX;uJGF{e2G7 NX7sfGhYOSCq MnK0SG1UVw>? NI\ZcYxKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hf2m2aDDFR|UxKG:oIECuNFU2KM7:TR?= MXSyOFkxODJ4Nh?=
DU145 NFu1fWdHfW6ldHnvckBCe3OjeR?= M2HER|EhcA>? Mn7ESG1UVw>? NEnKdYRKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hTFVzNEWgZ4VtdHNiaHHyZo9zcW6pIFzLRlEhdXW2YYTpc44hf2m2aDDFR|UxKG:oIECuNFc{KM7:TR?= NXX3cY5POjR7MECyOlY>
A2780 NXSycZpzTnWwY4Tpc44hSXO|YYm= MVGxJIg> MVnEUXNQ NHLMc|ZKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gRVI4QDBiY3XscJMhf2m2aDDFR|UxKG:oIECuNFc1KM7:TR?= M1fH[VI1QTByMk[2
MCF7 NVPFSmNuTnWwY4Tpc44hSXO|YYm= NV;LRXI3OSCq NUjTUIs6TE2VTx?= M2KwcWlvcGmkaYTpc44hd2ZiUFmzT4FteGijIFW1OFVMKG23dHHueE1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6xJO69VQ>? NIDmWI4zPDlyMEK2Oi=>
U87MG Ml;PSpVv[3Srb36gRZN{[Xl? MXKxJIg> NEGwc|BFVVOR NGmxcmFKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDFR|UxKG:oIECuNVMh|ryP NID6cIMzPDlyMEK2Oi=>
A2780 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzPO|IhcA>? M2XmW2ROW09? MVfFR|UxRTBwNUKg{txO M4m5XFI1QTByMk[2
SKMES-1 Mo\JR5l1d3SxeHnjJGF{e2G7 NX;Lbo9IOSEQvF2= M1LNZlczKGh? NF:xc2NKdmS3Y3XzJINmdGxiZHXheIg> NXj3cXRjOjZyMUOzNVg>
H596 MXLGeY5kfGmxbjDBd5NigQ>? MWGxJO69VQ>? NVjOU5RwUW2yYXnyd{Bk\WyuIH3p[5JifGmxbh?= NWewZ2g1OjZyMUOzNVg>
HCC2450 NUTQ[WdJTnWwY4Tpc44hSXO|YYm= MYixJO69VQ>? NXzLUplIUW2yYXnyd{Bk\WyuIHnueoF{cW:w M3fh[VI3ODF|M{G4
A549 NH\1cVlHfW6ldHnvckBCe3OjeR?= NH7JPYE2ODBibl2= MmnMOFghcA>? NVT5RWRzTE2VTx?= NEfQWIlKdmirYnn0d{BCc3RiYXP0bZZifGmxbh?= NWjHU3c3OjV7M{eyPVk>
A549 MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID2eIsyKM7:TR?= M3\4W|czKGh? NEHWTmhFVVOR MYPJcohq[mm2czDj[YxtKGe{b4f0bC=> NULheIxDOjV7M{eyPVk>
H522 NUXQPIt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULPZ5FiOSEQvF2= M{K3O|czKGh? MlnSSG1UVw>? NYXXcHFDUW6qaXLpeJMh[2WubDDndo94fGh? MknuNlU6Ozd{OUm=
LNCaP NVfYNIliTnWwY4Tpc44hSXO|YYm= MVOxJO69VQ>? M1LlRXN2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy| NYnXdVNyOjV|NkC3PVk>
LNCaP95 MoLFSpVv[3Srb36gRZN{[Xl? Mn;lNUDPxE1? M1Xm[3N2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy| NWLKNlI3OjV|NkC3PVk>
HCT-15 MWrBdI91d3OrczDBd5NigQ>? MWWxNEDPxE1? MV[0PEBp NVz6[pNPTE2VTx?= Mmr2TY5lfWOnczDhdI9xfG:|aYOgbY4hUEOWLUG1JINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? MnyyNlUyPTJ{NEW=
HCT-116 MmT0RZBwfG:|aYOgRZN{[Xl? MmLTNVAh|ryP MUS0PEBp NH7zS3pFVVOR NH;wUoVKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVE3KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= M3q4b|I2OTV{MkS1
NCI-H460 M2L3OmFxd3Sxc3nzJGF{e2G7 Mnj5NVAh|ryP M2jXcVQ5KGh? NYPscGdZTE2VTx?= MnX3TY5lfWOnczDhdI9xfG:|aYOgbY4hVkOLLVi0OlAh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= NFTkV24zPTF3MkK0OS=>
SKOV-3 MVzBdI91d3OrczDBd5NigQ>? M1f6SlExKM7:TR?= NXjHfnE5PDhiaB?= MXzEUXNQ MlG2TY5lfWOnczDhdI9xfG:|aYOgbY4hW0uRVj2zJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? Mm\NNlUyPTJ{NEW=
BSY-1 M3L6d2Fxd3Sxc3nzJGF{e2G7 M3zlWFExKM7:TR?= M{P5XlQ5KGh? MlTqSG1UVw>? MWXJcoR2[2W|IHHwc5B1d3OrczDpckBDW1lvMTDj[YxteyCqYYLic5VzcW6pIGDJT|NESSCqb4TzdI91KG23dHH0bY9v NEPBVW8zPTF3MkK0OS=>
MKN-1 MX7BdI91d3OrczDBd5NigQ>? NUnwcnpmOTBizszN M1vjclQ5KGh? NUDnWolETE2VTx?= NIXuUI9KdmS3Y3XzJIFxd3C2b4Ppd{BqdiCPS16tNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w MV6yOVE2OjJ2NR?=
NCI-H522 MnixRZBwfG:|aYOgRZN{[Xl? NFvidZQyOCEQvF2= M1HjN|Q5KGh? MVnEUXNQ M4fEPWlv\HWlZYOgZZBweHSxc3nz NEH2dYczPTF3MkK0OS=>
OVCAR-3 MlLRRZBwfG:|aYOgRZN{[Xl? M1v1SFExKM7:TR?= MoXaOFghcA>? NWTabVF1TE2VTx?= M3fGOWlv\HWlZYOgZZBweHSxc3nz MkG0NlUyPTJ{NEW=
HBC-5 NX7o[XZzSXCxdH;zbZMhSXO|YYm= M13Rb|ExKM7:TR?= M4jRPVQ5KGh? NUPuXHVHTE2VTx?= NFrt[Y1KdmS3Y3XzJIFxd3C2b4Ppdy=> MXKyOVE2OjJ2NR?=
RXF-631L NFfoS3FCeG:2b4Ppd{BCe3OjeR?= NUnJcIxvOTBizszN NELMdWQ1QCCq MYTEUXNQ MXTJcoR2[2W|IHHwc5B1d3Orcx?= MVSyOVE2OjJ2NR?=
MKN-45 Mlz4RZBwfG:|aYOgRZN{[Xl? MoTzNVAh|ryP M{\6S|Q5KGh? M2HC[2ROW09? M{eyVWlv\HWlZYOgZZBweHSxc3nz NGHDeY8zPTF3MkK0OS=>
BON-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjN[HA2ODBibl2= MkXyNVAh\A>? M3fSN2ROW09? M2TZZWlvcGmkaYTzJINmdGxiZ4Lve5Rp M2HQd|I2ODJ4Mkmy
BON-1 NXXlcGh4TnWwY4Tpc44hSXO|YYm= MorIOVAxKG6P MlzLOEBp NF\qZVVFVVOR MXTJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGTodlMxQCCjbnSgV4VzPDd| NFr3eZczPTB{NkK5Ni=>
QGP-1 NYLCem8zTnWwY4Tpc44hSXO|YYm= Mn3tOVAxKG6P MoDvOEBp M3v6VWROW09? M{PaU2lvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgWIhzOzB6IHHu[EBU\XJ2N{O= M16ycFI2ODJ4Mkmy
Huh7 MULGeY5kfGmxbjDBd5NigQ>? MmPtNUDPxE1? MkPPNUBp M4HF[GROW09? MlHzTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDT[ZI1PzR? M1j1bFI2ODB2NECz
BNL M17XUGZ2dmO2aX;uJGF{e2G7 MniyNUDPxE1? MoL4NUBp M1PzOmROW09? NGPLclhKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhWzZ? NXjpc5JjOjVyMES0NFM>
MDA-MB-175 M4Kxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m1TlEh|ryP MWi1JIQ> NHHkPZhFVVOR MXXJR|UxRDFizszN MnTaNlQ5Pzl5OU[=
MDA-MB-134 M2\nPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LkeFEh|ryP NGP2dlA2KGR? NYPzUlloTE2VTx?= NHjacZhKSzVyPEGg{txO NIS2NYQzPDh5OUe5Oi=>
HCC1500 NXfsVmM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv4fmkyKM7:TR?= NEL4Z5o2KGR? NFvGZWFFVVOR Ml\qTWM2ODxzIN88US=> Moq2NlQ5Pzl5OU[=
EFM-19 Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSxJO69VQ>? MV:1JIQ> NF62WJVFVVOR NWTmW5NOUUN3MEyxJO69VQ>? NEDF[JIzPDh5OUe5Oi=>
ZR-75-30 NGLnTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:xJO69VQ>? MmLKOUBl MWHEUXNQ NWfxc5JQUUN3MEyxJO69VQ>? M33pS|I1QDd7N{m2
MDA-MB-361 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPkXXIyKM7:TR?= MVO1JIQ> MWPEUXNQ M2PnZ2lEPTB:MTFOwG0> Mn22NlQ5Pzl5OU[=
T-47D M3yyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHvOm4yKM7:TR?= M1v5b|Uh\A>? NXXjS4tMTE2VTx?= Mo\STWM2ODxzIN88US=> MWGyOFg4QTd7Nh?=
SK-BR-3 MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz6fZhIOSEQvF2= NGLtNoc2KGR? M2\BPGROW09? MWLJR|UxRDFizszN NIr1NnMzPDh5OUe5Oi=>
UACC-732 MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPyVGUzOSEQvF2= NXrtNVF[PSCm M3vkTGROW09? NHXkemFKSzVyPEGg{txO M1W5XFI1QDd7N{m2
BT-474 M1fY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DZd|Eh|ryP NEPmOpU2KGR? NIPie5ZFVVOR MmixTWM2ODxzIN88US=> M3HvW|I1QDd7N{m2
HCC202 M1e0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33ufVEh|ryP MWe1JIQ> MV7EUXNQ M3XlO2lEPTB:MTFOwG0> MoexNlQ5Pzl5OU[=
MCF7 NWq2UZV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zNRlEh|ryP Mo\VOUBl M37KbmROW09? NHPpeHdKSzVyPEGg{txO NXLtO|hbOjR6N{m3PVY>
MDA-MB-415 NXX0UGFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3IcJA{OSEQvF2= M3ToVFUh\A>? MlHlSG1UVw>? NH;3TVNKSzVyPEGg{txO MkLINlQ5Pzl5OU[=
MDA-MB-453 M{fzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF73O4wyKM7:TR?= NFrzUoc2KGR? NUnmU|V6TE2VTx?= NGjqXmhKSzVyPEGg{txO MXKyOFg4QTd7Nh?=
ZR-75-1 MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHSdZgyKM7:TR?= M{OzSVUh\A>? M2LROmROW09? MYPJR|UxRDFizszN MmG2NlQ5Pzl5OU[=
HCC38 NIC4NZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrjXoIyKM7:TR?= NIfTUJY2KGR? MYfEUXNQ MVjJR|UxRDFizszN NYjJbJI5OjR6N{m3PVY>
HCC1419 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK4fokyKM7:TR?= MYS1JIQ> M2fOSGROW09? NV3VdoFVUUN3MEyxJO69VQ>? MnrlNlQ5Pzl5OU[=
UACC-812 NXTHWI5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWexJO69VQ>? M4TCXVUh\A>? NHP0TGpFVVOR NIDtTmhKSzVyPEGg{txO NWf2dJJwOjR6N{m3PVY>
HCC1187 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIj6TI0yKM7:TR?= Ml7wOUBl M1rqfWROW09? MYTJR|UxRDFizszN MVWyOFg4QTd7Nh?=
KPL-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTMNXZbOSEQvF2= M4DWdlUh\A>? MnuySG1UVw>? MorNTWM2ODxzIN88US=> M2W3TlI1QDd7N{m2
SUM-225 NHHuNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSxJO69VQ>? NF\5SYw2KGR? M1nzVWROW09? NUTTTodtUUN3MEyxJO69VQ>? NHXEcZczPDh5OUe5Oi=>
EFM-192A NUXISHpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3pcWo1OSEQvF2= MYi1JIQ> NEH6b29FVVOR NIHGdppKSzVyPEGg{txO NWLtN21QOjR6N{m3PVY>
JIMT-1 M2TMeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zP[|Eh|ryP NIi1co42KGR? MkDxSG1UVw>? Ml;5TWM2ODxzIN88US=> M3TB[FI1QDd7N{m2
HCC1143 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GxWVEh|ryP M{D3bFUh\A>? M{HpZmROW09? MVHJR|UxRDFizszN NWC2UodnOjR6N{m3PVY>
HCC2218 MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEOxWW4yKM7:TR?= MVW1JIQ> M4THd2ROW09? M{PufGlEPTB:MTFOwG0> MVSyOFg4QTd7Nh?=
MDA-MB-468 NUH6PJZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfpUXJ6OSEQvF2= MofROUBl M1;2VmROW09? MlrSTWM2ODxzIN88US=> NEXxO4IzPDh5OUe5Oi=>
BT-20 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3RU5UyKM7:TR?= MVG1JIQ> NF3CXJBFVVOR MVfJR|UxRDFizszN NGHIbI4zPDh5OUe5Oi=>
MDA-MB-435 MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X1VVEh|ryP NX;YWldlPSCm NVnmcFVITE2VTx?= NY\rTWlnUUN3MEyxJO69VQ>? M4PtTFI1QDd7N{m2
BT-549 M2fibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqxJO69VQ>? MXm1JIQ> NFvPbolFVVOR NWXQfG9TUUN3MEyxJO69VQ>? NFTiPJkzPDh5OUe5Oi=>
HCC1806 NIfiSWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHYO3J4OSEQvF2= MUK1JIQ> MkTISG1UVw>? NXvCfG5ZUUN3MEyxJO69VQ>? MojGNlQ5Pzl5OU[=
HCC1937 MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nF[|Eh|ryP MmTTOUBl M3r1OWROW09? MoPxTWM2ODxzIN88US=> NIixO3ozPDh5OUe5Oi=>
Hs578T Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO1O2w5OSEQvF2= M2HJSlUh\A>? NIfrWZFFVVOR NXXZWWhRUUN3MEyxJO69VQ>? MWWyOFg4QTd7Nh?=
LN18 M33lVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWyNEDPxE1? Mn;vO|IhcA>? MlvJSG1UVw>? MUTJR|UxRDVizszN NWTPWoE4OjR5NEGwO|Q>
LN229 NFflZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkmyNlAh|ryP MmTKO|IhcA>? MkX2SG1UVw>? MVzJR|UxRDVizszN NFXFVJAzPDd2MUC3OC=>
LNZ308 M{\mNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWiyNEDPxE1? MYO3NkBp MlLGSG1UVw>? MX\JR|UxRDVizszN NFXmSYwzPDd2MUC3OC=>
T98G M4S0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojyNlAh|ryP MX23NkBp NFXx[YFFVVOR NHvHbXFKSzVyPEWg{txO M1GyW|I1PzRzMEe0
U87 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvFT4gxOjBizszN M{XyOVczKGh? MoPDSG1UVw>? MV;JR|UxRDVizszN NXjmcW0yOjR5NEGwO|Q>
LN18 M2njUGZ2dmO2aX;uJGF{e2G7 M120Z|Uh|ryP Mne4NlQhcA>? NGr0cJZFVVOR MoPBTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? NETOeYkzPDd2MUC3OC=>
LNZ308 NFvkO|hHfW6ldHnvckBCe3OjeR?= NXLCVnZ3PSEQvF2= MnHENlQhcA>? NFPJcpZFVVOR NU\pOodvUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= NXKxcJJ1OjR5NEGwO|Q>
Saos-2 MkH4SpVv[3Srb36gRZN{[Xl? M1voTFUxKM7:TR?= MXS0PEBp M1nvT2lvcGmkaYTzJINmdGxiaX72ZZNqd25? NFe0SHYzPDd{N{[2NC=>
MG-63 NVHqcIpDTnWwY4Tpc44hSXO|YYm= NHPaTZI2OCEQvF2= NFewdnI1QCCq NVzyUFZyUW6qaXLpeJMh[2WubDDpcpZie2mxbh?= M1zic|I1PzJ5Nk[w
SJSA-1 M1HVfWZ2dmO2aX;uJGF{e2G7 MYW1NEDPxE1? M3LLSVQ5KGh? NWL6TYRGUW6qaXLpeJMh[2WubDDpcpZie2mxbh?= M3PJelI1PzJ5Nk[w
Saos-2 NXTP[3lDTnWwY4Tpc44hSXO|YYm= M{SwXFUxKM7:TR?= Ml3lOFghcA>? NGDBdI5KdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v Ml[yNlQ4Ojd4NkC=
MG-63 M{nydmZ2dmO2aX;uJGF{e2G7 MXu1NEDPxE1? Ml6zOFghcA>? NYPGeYNwUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? Mk\JNlQ4Ojd4NkC=
SJSA-1 M2fCdmZ2dmO2aX;uJGF{e2G7 NX3RRVJKPTBizszN M{C3RVQ5KGh? M2TEcWlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> Mnq4NlQ4Ojd4NkC=
Saos-2 NVnKVGdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3aUVd3PTBizszN NWfLOoxTPDhiaB?= MoPMTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NHnKPYYzPDd{N{[2NC=>
MG-63 Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXG1NEDPxE1? MlrSOFghcA>? Mlq5TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NXHtNHp3OjR5Mke2OlA>
SJSA-1 NFXWN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj1[YI2OCEQvF2= NGXjZVA1QCCq MYnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NIj6[lkzPDd{N{[2NC=>
FaDu Mn\xSpVv[3Srb36gRZN{[Xl? NUnpVZNLPSEQvF2= M3[4fFI1KGh? Mn\DSG1UVw>? MoPJVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= MkOzNlQ3OzFzNEe=
EMT6 NH3vPYpHfW6ldHnvckBCe3OjeR?= NHH0foE2KM7:TR?= NWG5ZmNqOjRiaB?= NHL3c2hFVVOR M2DvVHJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u NICxVVgzPDZ|MUG0Oy=>
HCT116 NV\kd2VpTnWwY4Tpc44hSXO|YYm= NUnWNmVGPSEQvF2= Mn;HNlQhcA>? NXqzc|JJTE2VTx?= M{PQSHJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u NWTXW4xUOjR4M{GxOFc>
U87 NYWwV3JHTnWwY4Tpc44hSXO|YYm= MUC1JO69VQ>? M2rVN|I1KGh? Mny4SG1UVw>? MnHiVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= Mn;KNlQ3OzFzNEe=
GBM M4\WdmFxd3C2b4Ppd{BCe3OjeR?= M3HudFLPxE1? M{TldFQ5cA>? MV7EUXNQ MYDpcoR2[2WmIHjp[4hmeiCuZY\lcJMhd2ZiYYDvdJRwe2m|LDDhcoQh\GWlcnXhd4VlKGOnbHygeoli[mmuaYT5 NIf1bIgzPDVyMES5Ni=>
BON NGjuVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6xMVXPxE1? MlSwO|Jp NXzJfoNS\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? MUiyOFQ1OzV{Mx?=
BON M3mxOWFxd3C2b4Ppd{BCe3OjeR?= MX[xMVXPxE1? M3\WR|I1cA>? NGq5VFdqdmO{ZXHz[ZMh[XCxcITvd4l{ MXOyOFQ1OzV{Mx?=
H1975 NUDjdFc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PIbFAvOy17LkdOwG0> MlrtO|Jp NEHPS2tFVVOR MUPJR|UxRTFwM{i1{txO M3HyO|I1OzN5OES2
H1975 MmrsRZBweHSxc3nzJGF{e2G7 MUmy{txO NG\jPGwzPGh? M4rHUGROW09? NI\vVXNqdmO{ZXHz[ZMh[XCxcITvd4l{KHKjdHWgd4lodmmoaXPhcpRtgQ>? M{fDTFI1OzN5OES2
T-ALL MWnBdI9xfG:|aYOgRZN{[Xl? MV7i[ZR4\WWwIEGuOEBidmRiNT6zJI1OKGG2IEK0bEBidmRiMD65JIFv\CB3LkWgcW0h[XRiNEjoJIlvKGSrZn\ldoVvfCClZXzsJIxqdmV? NILQTGUzPCCxcjC0PIg> M3vBeGROW09? MkfPZYZn\WO2czD0bIUhWEl|SzDwZZRpf2G7IHnuJHQuSUyOIHPlcIwhdGmwZYO= Mn35NlQ{OTB5M{[=
BCR-ABL M2rWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKwMlI2NTFyzszN NY\MRYJKPGR? NHfZXJh{cWewaX\pZ4FvfGy7IHnubIljcXRiY3XscEBxem:uaX\ldoF1cW:w Mly4NlQzPDR4MUK=
LC-1/SQSF M1ywcmZ2dmO2aX;uJGF{e2G7 MUOz{txO M1f2XlI1cA>? Mn\tSG1UVw>? NXrIcFVy\GWlcnXhd4UhVlKIMjDwdo91\WmwIHzleoVt MVSyN|k5ODB7Mx?=
Primary CLL cells NXz5VYd5SXCxcITvd4l{KEG|c3H5 M3LR[lEuOTEQvF2= NYizeGY6PDiq MWXpcoR2[2W|IHHwc5B1d3OrczDpckBEVExiY3XscJMhcW6mZYDlcoRmdnRib3[gdJJw\26xc4TpZ{Bu[XKtZYLz MlnhNlM5PTB6MEe=
Primary CLL cells MWfLbY5ie2ViQYPzZZk> M1HQb|LPxE1? MWmzNI1qdg>? NXHCW2FG\GWlcnXhd4VlKFCLM1ugZYN1cX[rdIm= NHvRT2EzOzh3MEiwOy=>
Primary CLL cells NF3XSGJEgXSxdH;4bYMhSXO|YYm= M4\DXFLPxE1? M2rlSVI1cA>? MYLpcoR2[2W|IHPlcIwh[3m2b4TvfIlkcXS7 MUmyN|g2ODhyNx?=
human NSCLC cell lines NFPXZVlCeG:ydH;zbZMhSXO|YYm= MUCwMlEzPS12zszN NF:xVHAzPGh? NFfmb5JFVVOR MVTJR|UxeyC{YX7n[ZMh\nKxbTCwMlQuOs7:TR?= MmHONlM2PjJ2N{K=
human HCC cell lines NWfwVlJsS2WubDD2bYFjcWyrdImgZZN{[Xl? M3XXPVAvODB3LUJOwG0> NHjjSo41QGh? NVrmd|FZUUN3ME2x{txO NIfEfGgzOzR6OUm5PS=>
Huh7 NYKxUI9FU2mwYYPlJGF{e2G7 MoTKNe69VQ>? MoL0OFhp MmTkd4lodmoxrJHjZY51dHlicnXkeYNmeyCyaH;zdIhwenmuYYTpc44hd2ZiQXv0 MViyN|Q5QTl7OR?=
SK-HEP1 M3Lhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP6d4EyNTJyzszN M2OyO|czcA>? MkLrSG1UVw>? NU[3eGJHUUN3MP-8oFHPxE1? NFn2VVEzOzR5OUGzOi=>
786-0 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTpNU0zOM7:TR?= MnjzO|Jp MVvEUXNQ MWnJR|Ux97zeMd88US=> M3LJOlI{PDd7MUO2
JVM2 Mn\VR5l1d3SxeHnjbZR6KGG|c3H5 MmTrNE4zNTJyzszN M13xRVczcA>? NWPLb3d2TE2VTx?= MVjJR|UxRTBwOd88US=> M4TISVI{OjN6NkO5
EHEB MonsR5l1d3SxeHnjbZR6KGG|c3H5 Mo[1NE4zNTJyzszN M3K5c|czcA>? MXLEUXNQ MV;JR|UxRTBwN988US=> M2DaWlI{OjN6NkO5
MEC2 NXey[YhYS3m2b4TvfIlkcXS7IHHzd4F6 NYjkXlVKOC5{LUKw{txO NYqwVGxoPzKq M4P0TGROW09? Mk\LTWM2OD1yLkhOwG0> MknDNlMzOzh4M{m=
primary B-CLL lymphocytes M1nSfmFxd3C2b4Ppd{BCe3OjeR?= MWLJR|UxKG[xcjDlZYNpKHC{aX3hdpkh[2WubDDsbY5m NXHqcG9iOjSq M3y0O2ROW09? MnL0TWM2OO,:nEROwG0h\m:{IHHscEBx[XSrZX70dy=> NFWwOG0zOzJ|OE[zPS=>
primary B-CLL lymphocytes MUHLbY5ie2ViQYPzZZk> M4nGbmlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV? NV3FdYw6OjSq M4nLR4lvcGmkaYTzJJA4OFN4SzCmJFRGNUKSMTDlfJBz\XO|aX;u MUKyN|I{QDZ|OR?=
human NSCLC M4DKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTyNE42NTMQvF2= M1HDZVczcA>? NVTkWI9jUUN3ME2x{txO MX2yNlc5OTN7Mx?=
human NSCLC M3y5cWtqdmG|ZTDBd5NigQ>? M{TsWlHPxE1? NXP6Z5hCOjSq MnfQbY5pcWKrdIOgeIhmKEGtdD;tWG9TKHOrZ37hcIlv\yCyYYToe4F6KGG2IEPoJIFnfGW{IITy[YF1dWWwdB?= MnnBNlI4QDF|OUO=
Y1 cell line M1rCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSwMlHPxE1xMd88US=> MV2yOIg> MY\EUXNQ NVznO5pvcW6qaXLpeJMhPjExvJWgZ4VtdCC4aXHibYxqfHliaX6gUZlkNVOldIKteJJidnOoZXP0[YQh[2WubIO= MmTQNlI3QTJ7MES=
PIK3CA-mutant MCF7 NXfST|hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTHTVUxRTF4MNMxPVFvVe,:jFzEOVA:QThywsGyO|NvVQ>? NVfyVWlKPzKq NG\j[VJIUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?= MVmyNlY2Ozl4Nx?=
PIK3CA-mutant MCF7 NI\y[HBMcW6jc3WgRZN{[Xl? MWHJR|UxRTFzNNMxN45O MmTLO|Jp NFLjNm5KSzVyPUGxOOKyO26PIHnuJJJm\HWlaX7nJGFsfCCyaH;zdIhwenmuYYTpc44hdGW4ZXzz NVq0OnpuOjJ4NUO5Olc>
MCF7-myr-Akt MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\HTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>? M1GzcVczcA>? MmH0S2k2OD1{OUpCtVY5dk4xvJzMSFUx97zgMUCsNFAxdk1? Mn23NlI3PTN7Nke=
colon cancer cell lines Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[wMVEx|ryP NUHEfoR{PzKq NIHKSXlFVVOR MVPJR|UxRTIQvF2= NWruUnRIOjJ3NEO4OVc>
gastric cancer cell lines NIXMTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXywMVEx|ryP MYO3Nog> Mo[0SG1UVw>? MX7JR|UxRTJvNd88US=> NFzaTWMzOjV2M{i1Oy=>
HCT-116/HT-29/MKN-45 M{nEPWFxd3C2b4Ppd{BCe3OjeR?= NVi4e4F7Os7:TR?= M2XI[VQ5cA>? M3LV[ZNpcW[2IHnuJGczKHCqYYPl MXiyNlU1Ozh3Nx?=
HT-29 and HCT-116 NELZN3lE[XOyYYPlJIF{e2G7 NVvybZBwPc7:TR?= M3z3[|I1cA>? MU\pcoR2[2W|IHPhd5Bie2ViYXP0bZZqfHl? MoqxNlI2PDN6NUe=
MM cell lines NIfqfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom1NVDPxE1? MWSyOIg> NHXjW3hFVVOR MXjJR|UxKH[jcnnld{BidW:wZzDkbYZn\XKnboSgZ4VtdCCuaX7ld{BqdiC2aX3lJIFv\CCmb4PlJIRmeGWwZHXuZ4U> NVrVRolFOjJ{MEe0PFU>
ARP-1 NHnycVNCeG:ydH;zbZMhSXO|YYm= M{HuW|Ex|ryP NVvJOmp6OjSq M4rHR2ROW09? MWXpcoR2[2W|IF3NJINmdGxiYYDvdJRwe2m|IITodo92\2hiY3HzdIF{\SCjY4TpeoF1cW:w NWrPR5hxOjJ{MEe0PFU>
SNU-601 M{nGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HkflczcA>? MYTEUXNQ M4nSV2lEPTB;MD64NVbDuTBwME[z{txO MmXTNlIyPTl6MUS=
SNU-1 NUWzZmY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvZO|Jp NVrteGVFTE2VTx?= MULJR|UxRTFwMEiyxtExNjB{ON88US=> NFzmc40zOjF3OUixOC=>
SNU-668 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq1O|Jp MlflSG1UVw>? M37MUmlEPTB;MT61O|nDuTBwMEe0{txO NUTuTYNyOjJzNUm4NVQ>
AGS MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojiO|Jp MWHEUXNQ M2LvOmlEPTB;MT63NVTDuTBwMUG3{txO M4HwXFIzOTV7OEG0
SNU-216 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfySVU4Omh? M3;1WGROW09? M2T4eWlEPTB;Mj62PVLDuTBwMEiy{txO NV\JO5FEOjJzNUm4NVQ>
SNU-5 MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[3Nog> MUTEUXNQ NHG3VHlKSzVyPUGuN|UyyrFyLkC5Ne69VQ>? M4Pkc|IzOTV7OEG0
SNU-638 NV[5b2o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7HOGc4Omh? NXridJN6TE2VTx?= Mn35TWM2OD1{LkK4NuKyOC5yNUROwG0> NXzDNZNFOjJzNUm4NVQ>
SNU-16 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWK3Nog> NXPiTo57TE2VTx?= MoPrTWM2OD1zLkW3N:KyOC5yMEJOwG0> MYGyNlE2QThzNB?=
SNU-484 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrPPVFnPzKq NX7COphITE2VTx?= NVzwOYFjUUN3ME2xMlczQMLzMD6wOFXPxE1? NES2cYEzOjF3OUixOC=>
SNU-620 MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVS3Nog> M17RSWROW09? M2jNO2lEPTB;Mj65N|nDuTBwMECx{txO M3;4SVIzOTV7OEG0
SNU-719 NH;heZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\sfnA4Omh? NFHKcI5FVVOR NVHnbGhqUUN3ME2zMlA{P8LzMD6wN|LPxE1? Mn24NlIyPTl6MUS=
glioma cell lines NH7UZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLMO|Jp NUDPZWF4UUN3ME2xMVLPxE1? M4\ZUFIzODZ3MEiw
U87 MXnBdI9xfG:|aYOgRZN{[Xl? NIO1NG4z|ryP NVTNdm1TPzKq M1vPWYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiYX7kJINt\WG4ZXSgVGFTWCCjbnSgZ4F{eGG|ZT2z MUeyNlA3PTB6MB?=

... Click to View More Cell Line Experimental Data

In vivo BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

Protocol

Kinase Assay:[1]
+ Expand

PI3K biochemical assay (ATP depletion assay):

BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:[1]
+ Expand
  • Cell lines: A2780 cells.
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3 days.
  • Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice.
  • Formulation: In 15% Captisol.
  • Dosages: ~60 mg/kg.
  • Administration: Dosed orally daily (q.d.).
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.39
Formula

C18H21F3N6O2

CAS No. 944396-07-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01870726 Terminated c-MET Inhibitor; PI3K Inhibitor PTEN Mutations Homozygous Del. of PTEN or PTEN Neg. by IHC c-Met Ampli. by FISH INC280 BKM120 Buparlisib; Recurrent GBM Novartis Pharmaceuticals|Novartis January 9 2014 Phase 1|Phase 2
NCT01820325 Terminated Non-Small Cell Lunch Cancer Novartis Pharmaceuticals|Novartis September 9 2013 Phase 1
NCT01512251 Completed BRAF Mutant Metastatic Melanoma University of California San Francisco|Novartis June 9 2012 Phase 1|Phase 2
NCT01610284 Active not recruiting Breast Cancer Novartis Pharmaceuticals|Novartis August 7 2012 Phase 3
NCT02340780 Active not recruiting Chronic Lymphocytic Leukemia Canadian Cancer Trials Group|Novartis January 30 2015 Phase 2
NCT01473901 Completed Glioblastoma Novartis Pharmaceuticals|Novartis December 30 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) supplier | purchase Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) cost | Buparlisib (BKM120, NVP-BKM120) manufacturer | order Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID